Brief: Kazia Therapeutics Launches New Paxalisib Phase Ii Clinical Trial
15/06/2021 02:45
June 15 (Reuters) - Kazia Therapeutics Ltd KZA.AX :
* KAZIA THERAPEUTICS LTD - KAZIA LAUNCHES NEW PAXALISIB
PHASE II
CLINICAL TRIAL-KZA.AX
* KAZIA THERAPEUTICS - ENTERED COLLABORATION WITH JOAN &
SANFORD I
WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY IN UNITED STATES
* KAZIA THERAPEUTICS - COLLABORATION TO LAUNCH PHASE II
CLINICAL
STUDY OF CO'S NEW DRUG, PAXALISIB, IN COMBINATION WITH
KETOGENESIS, FOR GLIOBLASTOMA
Source text for Eikon: ID:nASX79P1RR
Further company coverage: KZA.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Kazia Therapeutics
See all newsBrief: Kazia Therapeutics Files For Mixed Shelf Of Up To $100 Million – SEC Filing
Brief: Kazia Announces Voluntary Delisting From ASX
Australia's Kazia Therapeutics slumps to 1-yr low on delisting announcement
Brief: Kazia Therapeutics Announces Intention To Voluntarily De-List From ASX
Brief: Kazia Therapeutics Seeks Trading Halt